Brought to you by 
Medac licenses Acerus' Natesto in 15 European countries
15 Jul 2022
Executive Summary
Acerus Pharmaceuticals Corp. granted medac GMBH exclusive rights to its Natesto (testosterone) nasal gel in 15 European countries, including Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Italy, the Netherlands, Norway, Poland, Slovakia, Spain, Sweden, and the UK.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Nasal
- Topical Delivery
-
Drug Delivery
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Medac licenses Acerus' Natesto in 15 European countries
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice